In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Galapagos (GLPG). The company’s shares closed last Monday at $183.80, close to its 52-week high of $192.89.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.4% and a 46.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Galapagos is a Strong Buy with an average price target of $190.16, which is a 1.3% upside from current levels. In a report issued on November 6, Nomura also reiterated a Buy rating on the stock with a $209.00 price target.
See today’s analyst top recommended stocks >>
Based on Galapagos’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $402 million. In comparison, last year the company had a net profit of $17.26 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
